At <a href='https://www.linkedin.com/feed/hashtag/?keywords=APHRS2024&highlightedUp…; target='_blank'>#APHRS2024</a>, the CEASE-AF 24-month results were presented. The data demonstrated that Hybrid ablation with left atrial appendage exclusion is effective over the long term, with a ~33% absolute improvement in freedom from atrial arrhythmias* after 24 months of follow-up in patients with long-standing persistent Afib.**
Learn more about the CEASE AF Trial data: <a href="https://okt.to/cKo4mY" target="_blank">https://okt.to/cKo4mY</a>
*Freedom from atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) off anti-arrhythmic drugs (AADs) except previously failed AADs at doses not exceeding those previously failed
**Persistent atrial fibrillation with enlarged left atrium and longstanding persistent Afib
- Healthcare Professionals
- Therapies and Procedures
- Concomitant Surgical Ablation Therapy
- Ablation Sensing Unit & Switch Matrix
- cryoFORM® Cryoablation Probe
- cryoICE® BOX V6
- cryoICE® Cryoablation Probes
- Isolator® Linear Pen
- Isolator® Synergy™ Access® Clamp
- Isolator® Synergy™ Clamps (OLL2/OSL2)
- Isolator® Transpolar Pen (MAX3)
- Isolator® Synergy™ EnCompass® Clamp
- Multifunctional Ablation Generator (MAG)
- Hybrid AF™ Therapy
- Hybrid Total Thoracoscopic Therapy
- Left Atrial Appendage Management
- Cryo Nerve Block Therapy
- Concomitant Surgical Ablation Therapy
- Education & Training
- Clinical Evidence
- Product Labeling
- Resources
- Society Guidelines
- Therapies and Procedures
- Patients & Caregivers
- About AtriCure